CUSIP No. 89620X506

Page 2 of 8 Pages


1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Merlin Biomed Private Equity Advisors, LLC (IRS No. 13-4178606)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (A) o (B) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER - 0 -
		6	SHARED VOTING POWER 708,472
		7	SOLE DISPOSITIVE POWER - 0 -
		8	SHARED DISPOSITIVE POWER 708,472
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 708,472
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)			o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 16.60% (1)
12	TYPE OF REPORTING PERSON (See Instructions) IA

(1) The foregoing percentage is based upon 4,266,584 shares outstanding as of September 30, 2014, as set forth in the Issuer’s Form 20-F/A filed with the Securities and Exchange Commission (“SEC”) on November 26, 2014. The number of shares outstanding gives effect to a reverse stock split of the Issuer’s issued common shares on November 14, 2014 on the basis of 1 post-consolidation common share for 30 pre-consolidation common shares.

CUSIP No. 89620X506

Page 3 of 8 Pages


1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Merlin Nexus IV, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (A) o (B) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER - 0 -
		6	SHARED VOTING POWER 708,472
		7	SOLE DISPOSITIVE POWER - 0 -
		8	SHARED DISPOSITIVE POWER 708,472
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 708,472
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)			o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 16.60% (1)
12	TYPE OF REPORTING PERSON (See Instructions) OO

(1) The foregoing percentage is based upon 4,266,584 shares outstanding as of September 30, 2014, as set forth in the Issuer’s Form 20-F/A filed with the SEC on November 26, 2014. The number of shares outstanding gives effect to a reverse stock split of the Issuer’s issued common shares on November 14, 2014 on the basis of 1 post-consolidation common share for 30 pre-consolidation common shares.

CUSIP No. 89620X506

Page 4 of 8 Pages


1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Dominique Sémon
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (A) o (B) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER - 0 -
		6	SHARED VOTING POWER 708,472
		7	SOLE DISPOSITIVE POWER - 0 -
		8	SHARED DISPOSITIVE POWER 708,472
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 708,472
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)			o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 16.60% (1)
12	TYPE OF REPORTING PERSON (See Instructions) IN

(1)The foregoing percentage is based upon 4,266,584 shares outstanding as of September 30, 2014, as set forth in the Issuer’s Form 20-F/A filed with the SEC on November 26, 2014. The number of shares outstanding gives effect to a reverse stock split of the Issuer’s issued common shares on November 14, 2014 on the basis of 1 post-consolidation common share for 30 pre-consolidation common shares.

Item 1

(a).

Name of Issuer:

Trillium Therapeutics Inc.

Item 1

(b).

Address of Issuer’s Principal Executive Offices:

96 Skyway Avenue,
Toronto, Ontario M9W 4Y9
Canada

Item 2

(a).

Address of Issuer’s Principal Executive Offices:

This Schedule 13G is being filed by each of the following persons (each, a “Reporting Person” and together, the “Reporting Persons”):

(i)

Merlin BioMed Private Equity Advisors, LLC

(ii)

Merlin Nexus IV, L.P.

(iii)

Dominque Sémon

See Exhibit B for the Reporting Persons’ agreement for a joint filing of a single statement on their behalf.

(b).

Address of Principal Business Office:

424 West 33rd Street, Suite 520

New York, NY 10001

(c).

Citizenship:

Merlin BioMed Private Equity Advisors, LLC is a Delaware Limited Liability Company. Merlin Nexus IV, L.P. is a Delaware Limited Partnership. Dominique Sémon is a citizen of Switzerland.

(d).

Title of Class of Securities:

Common Stock, No Par Value (the “Common Stock”).

(e).

Title of Class of Securities:

89620X506

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership:

* See Attachment A.

(a)

Amount beneficially owned: 708,472

(b)

Percent of class: 16.60%

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote: -0-

(ii)

Shared power to vote or to direct the vote: 708,472

(iii)

Sole power to dispose or to direct the disposition of: -0-

(iv)

Shared power to dispose or to direct the disposition of: 708,472

Item 5.

Ownership of Five Percent or Less of a Class.

If this Statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. o

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Various other persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from sale of, the securities whose ownership is reported on this Schedule 13G. No other person’s interest in such securities relates to more than five percent of the class.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 17, 2014

	Merlin Biomed Private Equity Advisors, LLC

	By:	/s/ Dominique Sémon
		Name: Dominique Sémon
		Title: Managing Member

	Merlin Nexus IV, L.P.

	By:	Merlin Nexus IV, LLC, General Partner

		/s/ Dominique Sémon
	By:	Name: Dominique Sémon
		Title: Managing Member

	Dominique Sémon

	By:	/s/ Dominique Sémon
		Name: Dominique Sémon

ATTACHMENT A

As of December 31, 2014, Merlin Nexus IV, L.P. (“Merlin IV”) was the holder of 708,472 shares of Common Stock, no par value of Trillium Therapeutics Inc. (“Common Stock”). Merlin BioMed Private Equity Advisors, LLC, a Delaware limited liability company (“Merlin”) is the investment adviser to Merlin IV. Dominique Sémon is the Managing Member of Merlin. As of December 31, 2014, Merlin IV, Merlin and Dominique Sémon may be deemed, including by virtue of their mutual affiliation, as sharing voting power and dispositive power, and consequently to be beneficial owners, of the 708,472 shares of Common Stock held by Merlin IV, constituting 16.60% of the outstanding shares of Common Stock. The foregoing percentage is based upon 4,266,584 shares outstanding as of September 30, 2014, as set forth in the Issuer’s Form 20-F/A filed with the SEC on November 26, 2014. The number of shares outstanding gives effect to a reverse stock split of the Issuer’s issued common shares on November 14, 2014 on the basis of 1 post-consolidation common share for 30 pre-consolidation common shares.